Many thanks for you email regarding Immutep, which Matt has passed along to me.
GSK recently announced that the lead indication for GSK‘781 will be ulcerative colitis and anticipates that Proof of Concept data will be available in 2020.
While GSK hasn’t specifically stated that it will start a Ph2 trial in ulcerative colitis, Proof of Concept studies are typically a Ph2 trials.
I hope this helps,
Catherine
Column 1 Column 2 0 Catherine Strong
t: +61 2 8234 0100 m: +61 406 759 268
Level 15, 61 York Street, Sydney NSW 2000 Australia Level 1, 33 Richardson Street, West Perth WA 6005 Australia
www.CitadelMAGNUS.com @CitadelMAGNUS LinkedIn
Ann: TACTI-mel Patient Recruitment Complete & Operational Update, page-22
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.5¢ | 31.5¢ | $465.8K | 1.452M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 587491 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 18585 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
